Tadalafil for Enhancing Female Sexual Satisfaction
- 10 OVERDOSAGE
- Onset and Duration of Action for a 10mg Tadalafil Dose
- Tadalafil – Generic Cialis®
- Comparing Brand Cialis and Generic Tadalafil
- Potential Side Effects of Tadalafil
- 5 Reasons that Cialis Did Not Help You with Erections Or Stopped Working
- Patient Experiences and Reviews of Sublingual Tadalafil
- Tadacip 20mg Tablets
- Tadalafil for Erectile Dysfunction: Dosage, Indian Brands, and Safety Guide
- Cost and Accessibility of Low-Dose Tadalafil Treatment
- Tadalafila 20mg.
- DOSAGE AND ADMINISTRATION
- DOSAGE AND ADMINISTRATION
- Lectors and Commentators
- Cialis Dosage
- Should you take a daily erectile dysfunction pill?
- Tadalafil and Hormonal Interactions in Female Physiology
- TADALAFIL / 5mg; 10mg; 20mg Tablet
- Safety Profile and Recommended Dosage Guidance
- Understanding How Tadalafil Tablets Work
- On Sale Product
- Should you take a daily erectile dysfunction pill?
They do not directly cause penile erections, however, they affect the response to sexual stimulation. During sexual stimulation, nitric oxide is produced, which then activates cyclic guanosine monophosphate (cGMP). This results in smooth muscle relaxation and increased blood flow.5 Phosphodiesterases, however, catalyze the breakdown of cGMP to its corresponding monophosphate, GMP. There are several PDE isoenzymes, and PDE-5 is the isoenzyme present in highest concentrations in the smooth muscle of the corpora cavernosum of the penis.
Common Side Effects of Tadalafil
Effects of sildenafil on esophageal motility of normal subjects. Rochester, MI: JHP Pharmaceuticals, LLC; 2014 Sept. 12.Curless RV, Beaumont DM, Sinar EJ, et al. Subarachnoid hemorrhage mimicking acute water intoxication during labour augmented by oxytocin infusion. 13.Padma-Nathan H, McMurray JG, Pullman WE, et al. The PDE-5 inhibitors, sildenafil, vardenafil, and tadalafil mimic the structure of cGMP and competitively inhibit its breakdown by PDE-5 in the corpus cavernosum and related vessels, leading to increased dilatation and blood flow. This allows the induction of an erection during sexual stimulation.7 Sildenafil, vardenafil, and tadalafil all affect ED through the same basic mechanism of inhibiting PDE-5 but have differing potencies and affinities for each of the 11 PDE isoenzymes. Vardenafil is the most potent PDE-5 inhibitor, followed by sildenafil and tadalafil.7 However, there is no current evidence that greater drug potency has produced improved clinical efficacy. The affinities vary for the other PDE isoenzymes, and thus may explain the potential differences in their side effect profiles. While sildenafil, vardenafil, and tadalafil are all hepatically metabolized, there are variances in their pharmacokinetic profiles. Sildenafil is approximately 75% metabolized, predominantly by cytochrome P450 (CYP) 3A4 with contribution from CYP 2C9.7,8 Vardenafil is primarily metabolized by CYP 3A4 and secondarily by CYP 3A5 and 2C isoforms.7,9 Tadalafil is also metabolized by CYP 3A4.2,10 With CYP 3A4 being the major enzyme responsible for the metabolism of all three agents, they will potentially have many of the same drug interactions with some possible contributions from the minor enzymatic pathways. Other pharmacokinetic differences include time to maximum concentration and half-life. The slightly faster time to maximum concentration of vardenafil (0.7 hours) compared to sildenafil (0.8 hours) is likely clinically irrelevant, while tadalafil has the slowest onset and may require 2 hours to reach maximum concentration. Tadalafil, however, has the longest half-life (17.5 hours), followed by vardenafil (4 hours) and sildenafil (3.7 hours).7-10 These differences will account for variation in dosage timing and duration of effect. The considerably longer duration of effect for tadalafil will likely allow less frequent dosing and greater impulsiveness between partners, but also could potentially prolong adverse effects. There are no comparative trials evaluating sildenafil, vardenafil, and tadalafil; therefore, it is difficult to compare the individual trials available due to differences in study design and methodology. However, all three agents have been proven effective in treating ED in clinical trials based on the Erectile Function domain score of the International Index of Erectile Function, a sexual function questionnaire commonly used throughout the studies. Efficacy rates for the PDE-5 inhibitors vary widely throughout the literature with a range of 57% to 83%.5,11-13 Additionally, they have all shown efficacy in the treatment of ED in men with diabetes mellitus; however, no particular agent has yet to be recommended for patients with cardiovascular disease.2,8,10,12,14,15 Comparative trials are required to determine if a specific agent possesses better efficacy. There are drug-drug interactions with each of these medications, many of which involve the same drugs due to CYP 3A4 being the major enzymatic pathway for all of these agents. Due to the potential for severe hypotension, sildenafil and organic nitrates (e.g., nitroglycerin, isosorbide dinitrate [Isordil®, Sorbitrate®], and isosorbide mononitrate [Imdur, ISMO®, Monoket®]) are contraindicated (i.e., should not be taken together), and sildenafil doses > 25 mg should not be used within 4 hours of taking an alpha-blocker (e.g., prazosin [Minipress®], terazosin [Hytrin®], and doxazosin [Cardura®]).
What are the Projected Price Trends for Tadalafil?
On-demand IC351 (Tadalafil) enhances erectile function in patients with erectile dysfunction. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (Viagra): a report of seven new cases. Tadalafil associated with anterior ischemic optic neuropathy. 16.Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Sildenafil is a substrate of CYP 3A4 and 2C8/9 as well as an inhibitor of CYP 1A2, 2C8/9, 2C19, 2D6, 2E1, and 3A4; therefore, increased effects and possible toxicity of sildenafil occur when used concomitantly with drugs that inhibit these enzymes (e.g., cimetidine [Tagamet®], erythromycin, ketoconazole [Nizoral®], itraconazole [Sporanox®], amprenavir [Agenerase®], indinavir [Crixivan®], saquinavir [Fortovase®], and ritonavir [Norvir®]). Enzyme-inducing agents, such as St. John's wort and rifampin, may have the opposite effect and cause decreased sildenafil levels. Drug-food interactions with sildenafil can also occur. The rate and extent of absorption of sildenafil is reduced when taken with a high-fat meal and grapefruit juice may cause increased serum concentrations of sildenafil, consequently, concurrent use should be avoided.8-10,16-18 Concomitant use of vardenafil is also contraindicated with alpha-blockers and organic nitrates due to the potential for severe hypotension. Vardenafil is a substrate of CYP 3A4, and to a minor extent the 2C isoforms, leading to interactions with drugs that induce or inhibit these enzymes. Other enzyme inhibitors that may increase vardenafil levels are amiodarone (Cordarone®), cimetidine (Tagamet®), clarithromycin (Biaxin®), delavirdine (Rescriptor®), diltiazem (e.g., Cardizem®, Cardizem® SR, Cardizem® CD, Cardizem® LA, Cartia XT, Dilacor® XR, Diltia XT, Taztia XT, and Tiazac®), fluoxetine (Prozac®), fluvoxamine (Luvox®), nefazodone (Serzone®), nevirapine (Viramune®), saquinavir (Fortovase®), verapamil (Calan®, Covera-HS, Isoptin®SR, Verelan®), and grapefruit juice, but there are no current recommendations for dosage adjustments with these agents.8-10,16-18 Tadalafil is also metabolized by CYP 3A4, resulting in the potential for an interaction with any drug that induces or inhibits this isoenzyme. Ketoconazole (Nizoral®) and ritonavir (Norvir®) have both been shown to increase tadalafil levels; other CYP 450 inhibitors (e.g., erythromycin, itraconazole [Sporanox®], and grapefruit juice), however, have yet to be evaluated, but it is likely that they will also increase tadalafil levels. Patients taking potent inhibitors of CYP 3A4 (e.g., ketoconazole [Nizoral®] or ritonavir [Norvir®]) will require a dose adjustment of tadalafil.
Dosage and Administration
Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice. Volume VII, Number 2 March/April 2004 Christina Collins, Pharm.D. Erectile dysfunction (ED) is a common disorder that affects up to 30 million men in the United States alone.1,2 ED is defined as the inability to achieve or maintain a penile erection sufficient for sexual function.3 The prevalence of this disorder increases with age and predominantly affects men over the age of 40.4,5 In addition to age, there are some disease states that predispose men to develop ED, including hypertension, diabetes mellitus, and atherosclerosis. Smoking, excessive alcohol intake, and some medications (e.g., thiazide diuretics, calcium channel blockers, beta-blockers, digoxin, selective serotonin reuptake inhibitors, and tricyclic antidepressants) may also contribute to the development of ED.4,6 ED may be categorized into three types based on the causative factors: organic, psychogenic, and multifactorial.4,6 Organic causes include diabetes, hypertension, spinal cord injuries, and some medications. Depression, psychological stress, relationship problems, and performance anxiety are all of psychogenic origin.5 Multifactorial causes are any combination of the above. The dose should not exceed 10 mg and should not be administered more frequently than every 72 hours.
2. Upsides
With greater public awareness and discussion of ED, the demand for new and improved treatments has increased tremendously. The phosphodiesterase type 5 (PDE-5) inhibitor sildenafil (Viagra®) has become the drug of choice for treatment of ED since it reached the market in March of 1998. This is due to sildenafil's convenience and tolerability compared to previous therapies.5 It has been shown to be beneficial in the treatment of organic and psychogenic ED.5,6 Sildenafil does have some disadvantages such as side effects and a relatively short duration of action; consequently, the search for the ideal drug to treat ED has continued. This sustained pursuit has led to the development of two new PDE-5 inhibitors: vardenafil (Levitra®; Bayer Pharmaceuticals Corporation in cooperation with GlaxoSmithKline) was approved by the Food and Drug Administration (FDA) on August 19, 2003, and tadalafil (Cialis; Eli Lilly Corporation) was FDA-approved in November 2003.2 These new agents possess distinguishing characteristics that differentiate themselves from each other and sildenafil. Sildenafil, vardenafil, and tadalafil are all PDE-5 inhibitors indicated for the treatment of ED. Additionally, tadalafil is thought to increase the hypotensive effect of antihypertensive agents (e.g., calcium channel blockers, diuretics, angiotensin-receptor blockers, ACE-inhibitors, or adrenergic receptor-blocking agents) and therefore should be used with caution.